EcoDrugPlus

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSAOCG00000003070
Gene Symbol: NR3C2
3 Cross references
209 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSAOCG00000018264
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSAOCG00000006366
Gene Symbol: OPRK1
3 Cross references
196 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSAOCG00000008024
Gene Symbol: OPRL1
3 Cross references
190 Possible Orthologues:

Oxysterols Receptor Lxr-Alpha-Like

Ensembl ID : ENSAOCG00000017562
Gene Symbol: LOC111571031
3 Cross references
392 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSAOCG00000002898
Gene Symbol: OXTR
3 Cross references
186 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSAOCG00000004533
Gene Symbol: OXTR
4 Cross references
193 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSAOCG00000001505
Gene Symbol: PTH1R
3 Cross references
198 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSAOCG00000000854
Gene Symbol: PPARD
3 Cross references
392 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSAOCG00000022233
Gene Symbol: PPARG
4 Cross references
389 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSAOCG00000021870
Gene Symbol: LOC111573197
3 Cross references
384 Possible Orthologues:

Peroxisome Proliferator-Activated Receptor Alpha-Like

Ensembl ID : ENSAOCG00000005570
Gene Symbol: LOC111577779
3 Cross references
397 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).